Table 2.
Clinical trials of adenosine receptor ligands: example of recently completed or ongoing studies.
| Target | Ligands | Clinical Trials: Study | C. T. Identifier Code | Ref. |
|---|---|---|---|---|
| All adenosine receptor subtypes | Agonist: adenosine | Prophylactic Intra-coronary Adenosine to Prevent Post Coronary Artery Stenting Myonecrosis | NCT00612521 | [90] |
| Circulating Adenosine Levels Before and After Intravenous (IV) Persantine | NCT00760708 | [91] | ||
| All adenosine receptor subtypes | Antagonist: caffeine | Caffeine for Motor Manifestations of Parkinson’s Disease | NCT01190735 | [92] |
| Caffeine for Excessive Daytime Somnolence in Parkinson’s Disease | NCT00459420 | [93] | ||
| The Impact of Caffeine on Brachial Endothelial Function in Healthy Subjects and in Patients With Ischemic Heart Disease | NCT00564824 | [94] | ||
| Caffeine as a Therapy for Parkinson’s Disease | NCT01738178 | [95] | ||
| Adenosine A1 receptor | Agonist: BAY1067197 | Multiple Dose Study in Heart Failure of BAY 1067197 (PARSiFAL) | NCT02040233 | [96] |
| Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker | NCT01945606 | [97] | ||
| A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction (PANTHEON) | NCT02992288 | [98] | ||
| Adenosine A1 receptor | Agonist: tecadenoson | Safety Study of Tecadenoson to Treat Atrial Fibrillation | NCT00713401 | [99] |
| Adenosine A1 receptor | Antagonist: PBF-680 | “First-in-human” Study To Assess the Safety and Tolerability of PBF-680 in Male Healthy Volunteers | NCT01845181 | [100] |
| A Study to Assess the Efficacy of a 5-day, 10-mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients. | NCT02635945 | [101] | ||
| Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5′-Monophosphate Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics | NCT01939587 | [102] | ||
| Adenosine A2A receptor | Agonist: regadenoson | Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease | NCT01085201 | [103] |
| ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI) | NCT00208312 | [104] | ||
| Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson | NCT00881218 | [105] | ||
| Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D) (RABIT1D) | NCT01019486 | [106] | ||
| A Phase II Trial of Regadenoson in Sickle Cell Anemia | NCT01788631 | [107] | ||
| Adenosine A2A receptor | Agonist: binodenoson | Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia (VISION-305) | NCT00944970 | [108] |
| Adenosine A2A receptor | Agonist: MRE0094 | Safety and Efficacy Study of MRE0094 to Treat Chronic, Neuropathic, Diabetic Foot Ulcers | NCT00312364 | [109] |
| Adenosine A2A receptor | Antagonist: preladenant | A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513) | NCT01465412 | [110] |
| Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson’s Disease (P07037) | NCT01227265 | [111] | ||
| A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson’s Disease (PD) in Japanese Patients (P06402) | NCT01294800 | [112] | ||
| Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628) | NCT00686699 | [113] | ||
| Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145AM1) (COMPLETE) | NCT00693472 | [114] | ||
| A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson′s Disease (PD) (P05664) (PARADYSE) | NCT01155479 | [115] | ||
| Adenosine A2A receptor | Antagonist: istradefylline | Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline | NCT02256033 | [116] |
| A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson′s Disease (KW-6002) | NCT01968031 | [117] | ||
| Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson′s Disease | NCT02610231 | [118] | ||
| Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome | NCT00199446 | [119] | ||
| Adenosine A3 receptor | Agonist: CF101 | Trial of CF101 to Treat Patients With Psoriasis | NCT00428974 | [120] |
| Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients | NCT00556894 | [121] | ||
| Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure | NCT01033422 | [122] | ||
| Trial of CF101 to Treat Patients With Dry Eye Disease | NCT01235234 | [123] | ||
| Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca | NCT00349466 | [124] | ||
| Adenosine A3 receptor | Agonist: CF102 | A Phase 1–2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma | NCT00790218 | [125] |
| A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 | NCT00790673 | [126] | ||
| Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | NCT02128958 | [127] | ||
| Adenosine A3 receptor | Antagonist: PBF-677 | “First-in-human” Study To Assess the Safety and Tolerability of PBF-677 in Healthy Volunteers | NCT02639975 | [128] |